Cedars-Sinai/UCLA, 8641 Wilshire Blvd., Suite 301, Beverly Hills, CA 90211, USA.
Rev Endocr Metab Disord. 2010 Dec;11(4):275-80. doi: 10.1007/s11154-010-9138-0.
It is widely acknowledged that compliance and persistence with oral osteoporosis medications, particularly with bisphosphonates, is poor. Several excellent reviews have been written on compliance and persistence with osteoporosis medications and have discussed improvements seen with extended dosing intervals. This review begins with studies on extended dosing intervals to examine the limitations of administrative claims data. It also looks at compliance and persistence across multiple medical conditions, examining the importance of prescription fulfillment, intentional choice, causation and possible interventions.
人们普遍认为，口服骨质疏松症药物（尤其是双膦酸盐类药物）的依从性和持久性都很差。已经有几篇关于骨质疏松症药物的依从性和持久性的优秀综述，并讨论了延长给药间隔所带来的改善。这篇综述首先研究了延长给药间隔，以检查行政索赔数据的局限性。它还考察了多种医疗条件下的依从性和持久性，研究了处方兑现、有意选择、因果关系和可能的干预措施的重要性。
